Description du projet
Une technologie d’ingénierie cellulaire abordable
L’ingénierie des cellules immunitaires pour lutter contre le cancer a engendré des résultats prometteurs, apportant une opportunité thérapeutique là où la chimiothérapie échoue. La fabrication des thérapies cellulaires reste toutefois très coûteuse, nécessitant des méthodes d’ingénierie plus rentables. La mission du projet SOLUPORE, financé par l’UE, consiste à produire la prochaine génération de thérapies cellulaires à un meilleur coût. La plateforme SOLUPORE n’utilise pas de vecteurs viraux mais une nouvelle technologie pour délivrer de l’ARNm, de l’ADN ou des protéines aux cellules T et NK primaires, en conservant une viabilité et une fonctionnalité cellulaires élevées. La simplicité de la méthode SOLUPORE la rend conviviale et applicable à la fabrication d’immunothérapies.
Objectif
There is encouraging news for cancer patients, a new treatment, cell immunotherapy, has been delivering spectacular
clinical results and is a game changer because it is an entirely new way of treating cancer. Cancer immunotherapy, in which
a patient’s own immune cells are ‘armed’ by cell engineering to target and kill cancer cells, gives levels of complete response
in patients. The first cell immunotherapy drug was approved in August 2017 at a price of $475,000 per treatment. To bring
these life-changing treatments to patients and relieve the European and global healthcare burden they must become
available at affordable costs. The one thing worse than failure is unaffordable success and the challenge with these
treatments is the complex and high-cost of manufacturing. Current cell engineering methods are very expensive to
manufacture. Avectas has developed Solupore, a cell engineering technology, which delivers cargo to cells and plays a
critical role in the manufacturing process. The technology works by temporarily making the cell membrane permeable and
allowing cargo into the cell. Crucially, cell health and functionality are preserved while there is a significant improvement on
the process time and costs. Avectas has demonstrated that the pilot system can successfully deliver clinically relevant cargo
to T cells. During this project, Avectas will scale and align Solupore to regulatory compliance enabling us to commercialise
it. The emerging and fast-growing cell immunotherapy market is set to be worth $20bn in 2020, with cell manufacturing
representing $5bn. Commercialisation of Solupore will take 1% of the €5bn market share by 2024 and will generate global
revenues for Avectas, building value for the company and creating highly skilled jobs which will result in a high-value,
knowledge-based EU company. There will be substantial European and global socio-economic impact on cancer patients
living longer, better quality lives.
Champ scientifique
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
W23 F2H6 Kildare
Irlande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.